News

The transformation of a pharmaceutical giant's former headquarters is setting records in New York City's real estate market, with developers securing an enormous loan to make it happen. NYC leads ...
What was holding up a deal appeared to be the lack of affordable units, as a previous proposal called for 420. However, NYC's ...
Charney and Tavros spent years assembling properties for the Court Square high-rise, beginning in 2016. Eventually, they ...
While overall office demand has even exceeded pre-pandemic levels in NYC — not all properties are created equal. Currently, 5 ...
The incentive made New York’s largest project of 2024 — Metro Loft and David Werner’s conversion of the Pfizer building — a definite go, according to Metro Loft principal Nathan Berman.
taking the entire 12th floor of the 450K SF Midtown South office tower. The deal is Optiver’s first long-term NYC lease and will be in a prebuilt suite in the 20-story building. Digital media ...
The onychomycosis treatment products market is expected to reach USD 6,400.8 million by 2025 and is expected to steadily grow at a CAGR of 4.9% to reach USD 10,329.3 million by 2035. In 2024, ...
New stores are opening across the city at an impressive pace, many of them in locations now newly accessible to certain ...
WASHINGTON — The release of COVID-19 vaccine results after the 2020 election may have not been a “coincidence” — and could have been part of an effort by senior Pfizer executives to ...
Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...
Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...
Jeff Kindler, a biopharma executive who helped steer Pfizer’s $68 billion merger with Wyeth, is looking for a healthy return on his Upper West Side home. Kindler and his wife, Sharon Sullivan ...